(Bloomberg) -- Clayton Dubilier & Rice is nearing a deal to acquire control of Sanofi’s consumer health unit after the American buyout firm signed social commitments with the French government, according to people familiar with the matter.

CD&R agreed to pledges around local jobs, investments and production  linked to the consumer health unit Opella with the French government late Sunday, the people said, asking not to be identified because the information is private. Sanofi and the U.S. buyout firm are set to announce exclusivity as early as Monday, they said.

State-owned investment firm Bpifrance SACA is set to take a small stake in the OTC unit as part of the deal, the people said. Representatives for Sanofi and PAI declined to comment while CD&R couldn’t be immediately reached.

The consumer health unit is valued at around €15 billion ($16.3 billion), Bloomberg News has reported. Sanofi confirmed earlier this month it’s in talks to sell a 50% controlling stake in the business to CD&R, which beat out PAI Partners in the year-long bidding process. 

After Sanofi’s decision, the PAI-led consortium unexpectedly submitted an improved offer for Opella with additional pledges around jobs and investments. 

That prompted a statement from Sanofi saying that all candidates had the same opportunity to submit their best offers by the deadline. The French company said it’s “surprising that a ‘revised offer’” was made public through the media, “outside the timeframe and the governance process that framed the decision.”

--With assistance from Swetha Gopinath.

©2024 Bloomberg L.P.